CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2825-2833

  Höomberg, Nadine ^a   Adam, Christian ^a   Riedel, Tanja ^a   Brenner, Christoph ^a   Flatley, Andrew ^a   Röcken, Martin ^b   Mocikat, Ralph ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adaptive antitumor immunity; CTL response; DC maturation; Interferon ; myc mouse

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON;

ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNOLOGY; LYMPHOMA, B-CELL; METABOLISM; MOUSE; NATURAL KILLER CELL; ONCOGENE MYC; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD40; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; FEMALE; GENES, MYC; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84908679419     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28932     Document Type: Article

References (35)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
2. Boussiotis VA, Barber DL, Nakarai T, et al. Prevention of T cell anergy by signaling through the γc chain of the IL-2 receptor. Science 1994;266: 1039-42.
3. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
4. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-80.
5. + T-helper and a T-killer cell. Nature 1998; 393:474-8.
6. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
7. Adam C, Mysliwietz J, Mocikat R. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. J Translat Med 2007;5:16.
8. Ossevoort MA, Feltkamp MC, van Veen KJ, et al. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995;18: 86-94.
9. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1: 1297-302.
10. Gong, J, Chen L, Chen D, et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther 1997;4:1023-8.
11. Ribas AL, Butterfield H, McBride WH, et al. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther 1999;6:523-36.
12. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183: 87-97.
13. Piccioli D, Sbrana S, Melandri E, et al. Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195: 335-41.
14. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195: 327-33.
15. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-51.
16. Glas R, Franksson L, Une C, et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK cell-mediated responses. J Exp Med 2000;191:129-38.
17. Mocikat R, Braumüller H, Gumy A, et al. Natural killer cells activated by MHC class I-low targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003;19:561-9.
18. + T-cell-independent pathway for antitumor CTL induction. Blood 2005;106:338-44.
19. Karimi K, Boudreau JE, Fraser K, et al. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN-γ-producing NK cells. Mol Ther 2008;16:411-8.
20. Shimizu K, Fujii S. DC therapy induces longterm NK reactivity to tumors via host DC. Eur J Immunol 2009;39:457-68.
21. Egeter O, Mocikat R, Ghoreschi K, et al . Eradication of disseminated lymphomas with CpG-DNA- activated Th1 cells from non-transgenic mice. Cancer Res 2000;60:1515-20.
22. Ziegler A, Heidenreich R, Braumüller H, et al. EpCAM, a human tumor-associated antigen, promotes Th2 development and tumor immune evasion. Blood 2009;113:3494-502.
23. van den Broeke LT, Daschbach E, Thomas EK, et al. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 2003; 171:5842-52.
24. Dworacki G, Cicinnati VR, Beckebaum S, et al. Unpulsed dendritic cells induce broadly applicable anti-tumor immunity in mice. Cancer Biol Ther 2005;4:50-6.
25. Brenner C, King S, Przewoznik M, et al. Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol 2010;40: 494-504.
26. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979;122:549-54.
27. Strehl J, Selmayr M, Kremer J-P, et al. Gene therapy of B-cell lymphoma with cytokine genemodified trioma cells. Int J Cancer 1999;83:113-20.
28. Biedermann T, Kneilling M, Mailhammer R, et al. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000;192:1441-52.
29. Kovalchuk AL, Qi C-F, Torrey TA, et al. Burkitt lymphoma in the mouse. J Exp Med 2000;192: 1183-90.
30. Kremmer E, Mysliwietz J, Thierfelder S. Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice. Clin Exp Immunol 1997;109:180-4.
31. Przewoznik M, Hömberg N, Naujoks M, et al. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer. J Immunother 2012;35:217-22.
32. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE- 1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001;98:11521-6.
33. Cooper MA, Fehniger TA, Fuchs A, et al. NK cell and DC interactions. Trends Immunol 2004;25: 47-52.
34. Braumüller H, Wieder T, Brenner E, et al. Th1 cell cytokines drive cancer into senescence. Nature 2013;494:361-5.
35. -γsignaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008;13:507-18.